Enhanced Treatment and Prevention of Alzheimer's Disease

A comprehensive approach to treating and preventing Alzheimer's disease, incorporating cognitive training, genetic testing, and neuroprotective agents, while leveraging the benefits of aluminum salts in a pharmaceutical formulation.

The original patent disclosed a method for treating mild cognitive impairment using an aluminum salt. However, it had limitations in terms of patient selection, cognitive training, and prevention of β-amyloid deposition. The new inventive concept addresses these limitations by introducing a holistic approach to Alzheimer's disease treatment and prevention.

The new inventive concept comprises four main components: 1) a pharmaceutical formulation containing an aluminum salt in an amount from about 1.0 mg to about 5.0 mg, 2) a cognitive training program tailored to the patient's individual cognitive abilities, 3) a genetic test to identify the patient's risk profile for Alzheimer's disease, and 4) a neuroprotective agent selected from vitamin D, omega-3 fatty acids, and antioxidants. The combination of these components provides a comprehensive approach to treating and preventing Alzheimer's disease.

The new inventive concept introduces the novel combination of cognitive training, genetic testing, and neuroprotective agents with aluminum salts, which is not obvious from the original patent. The integration of these components provides a synergistic effect, enhancing the treatment and prevention of Alzheimer's disease.

Alternative embodiments of the inventive concept could include varying the type and amount of neuroprotective agents, incorporating additional cognitive training methods, or using different genetic tests to identify risk profiles. These variations would ensure broad conceptual coverage and adaptability to different patient populations.

The enhanced treatment and prevention of Alzheimer's disease has significant commercial potential in the pharmaceutical and healthcare industries. The target market includes patients diagnosed with Alzheimer's disease, mild cognitive impairment, or those at risk of developing the disease. The inventive concept could be marketed as a comprehensive treatment package, including the pharmaceutical formulation, cognitive training program, genetic testing, and neuroprotective agents.